Cognitive-Impairment Diagnostics For Schizophrenia
Summary
USPTO published patent application US20260090758A1 by Bristol-Myers Squibb Company for a method of diagnosing cognitive impairment in schizophrenia patients using electrical brain activity measurements. The invention processes neural activity data from electrodes attached to a patient's head along with stimulation data to determine modulation depth for cognitive assessment.
What changed
The patent application describes a diagnostic method that receives electrical activity data from electrodes on a patient's head representing neural activity in corresponding brain areas, along with stimulation data representing stimulation times applied to the patient. The method processes this data to determine a modulation depth and assess cognitive impairment due to schizophrenia. The CPC classifications indicate this falls under A61B (measuring/diagnosing), specifically EEG/electrical brain activity monitoring (A61B 5/291, A61B 5/388) and cognitive assessment technologies (A61B 5/4088).\n\nAs this is a patent application rather than enacted regulation, there are no immediate compliance obligations for healthcare providers or medical device manufacturers. However, companies developing similar neurodiagnostic or cognitive assessment technologies should monitor this application's prosecution to understand potential scope of any future granted claims that might affect their freedom to operate. The inventors are Ryan Allen Shewcraft, Mariann Micsinai Balan, and John Carter Schwarz.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Cognitive-Impairment Diagnostics For Schizophrenia
Application US20260090758A1 Kind: A1 Apr 02, 2026
Assignee
Bristol-Myers Squibb Company
Inventors
Ryan Allen Shewcraft, Mariann Micsinai Balan, John Carter Schwarz
Abstract
A method includes, for each corresponding electrode of one or more electrodes attached to a head of a patient, receiving corresponding electrical activity data representing neural activity within a corresponding area of a brain of the patient based on corresponding electrical activity measured by the corresponding electrode. The method also includes receiving stimulation data representing a plurality of stimulation times each corresponding to a stimulation applied to the patient while the one or more electrodes are attached to the head of the patient, and processing the corresponding electrical activity data and the stimulation data to determine a modulation depth for the patient. The method also includes assessing, based on the modulation depth, cognitive impairment of the patient due to a diagnosis of schizophrenia.
CPC Classifications
A61B 5/388 A61B 5/291 A61B 5/4088 A61B 5/6814 A61B 5/7253 A61B 5/7264
Filing Date
2025-10-01
Application No.
19347452
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Diagnosis & Surgery (A61B)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Diagnosis & Surgery (A61B) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.